Article

Polycystic ovary syndrome - Reply

University of Chicago, Department of Medicine, Section of Endocrinology, Chicago, USA.
New England Journal of Medicine (Impact Factor: 54.42). 04/2005; 352(12):1223-36. DOI: 10.1056/NEJMra041536
Source: PubMed
5 Followers
 · 
277 Views
  • Source
    • "PCOS affects between 6% and 10% of premenopausal women [1,2] and is a heterogeneous disorder with uncertain pathophysiology. Many women with PCOS also exhibit insulin resistance and glucose intolerance [3]. Moreover, 38% to 88% of women with PCOS are overweight or obese [4,5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The fat mass and obesity-associated (FTO) gene is associated with obesity and type 2 diabetes mellitus. Obesity and insulin resistance are also common features of polycystic ovary syndrome (PCOS). Therefore, the FTO gene might be a candidate gene for PCOS susceptibility. The aim of the present study was to evaluate the effects of FTO gene variants on PCOS susceptibility and metabolic and reproductive hormonal parameters. Methods We recruited 432 women with PCOS (24±5 years) and 927 healthy women with regular menstrual cycles (27±5 years) and performed a case-control association study. We genotyped the single nucleotide polymorphisms rs1421085, rs17817449, and rs8050136 in the FTO gene and collected metabolic and hormonal measurements. Results Logistic regression revealed that the G/G genotype (rs1421085, 1.6%), the C/C genotype (rs17817449, 1.6%), and the A/A genotype (rs8050136, 1.6%) were strongly associated with an increased risk of PCOS (odds ratio, 2.551 to 2.559; all P<0.05). The strengths of these associations were attenuated after adjusting for age and BMI. The women with these genotypes were more obese and exhibited higher free androgen indices (P<0.05) and higher free testosterone levels (P=0.053 to 0.063) compared to the other genotypes. However the significant differences disappeared after adjusting for body mass index (BMI). When we analyzed the women with PCOS and the control groups separately, there were no significant differences in the metabolic and reproductive hormonal parameters according to the FTO gene variants. Conclusion The rs1421085, rs17817449, and rs8050136 variants of the FTO gene were associated with PCOS susceptibility and hyperandrogenemia in young Korean women. These associations may be mediated through an effect of BMI.
    Diabetes & metabolism journal 08/2014; 38(4):302-10. DOI:10.4093/dmj.2014.38.4.302
  • Source
    • "Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women, producing symptoms of hyperandrogenism, oligo- or amenorrhoea and polycystic ovaries (PCO) (Franks 1995; Ehrmann 2005). Serum AMH levels and the ovarian antral follicle count (AFC) correlate closely both in healthy subjects and in women with PCOS (Pigny et al., 2003, 2006; Weenen et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: STUDY QUESTIONS Can serum anti-Müllerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome (PCOS)-associated features in adolescence and early adulthood?
    Human Reproduction 07/2014; 29(10). DOI:10.1093/humrep/deu182 · 4.59 Impact Factor
  • Source
    • "Polycystic ovary syndrome (PCOS) affects an estimated 6–18% of women of reproductive age and is a heterogeneous condition characterised by endocrine and metabolic disturbances [1] [2] [3]. Oligomenorrhoea and amenorrhoea are cardinal symptoms of PCOS and primary care management typically involves oral contraceptives and insulin-sensitising agents. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim We aim to evaluate the feasibility of, and pilot procedures for, a randomised study in the UK administering Chinese herbal medicine (CHM) to women with polycystic ovary syndrome (PCOS) related oligo- and/or amenorrhoea. Our primary aim of this feasibility study is to evaluate how appropriate oligo- and amenorrhoea is as the primary outcome of the main study. Materials and Methods A prospective, multi-centre, randomised, patient- and practitioner-blind, feasibility and pilot study will be conducted. 40 women with PCOS-related oligo- and/or amenorrhoea will be randomised to one of two parallel arms comparing standardised CHM treatment against individualised CHM treatment as usual for 6 months. Participants will be prescribed 8 g of CHM granulated extracts twice daily, totalling 16 g per day. Feasibility will be determined by collecting data on menstrual regularity, body mass index, waist hip ratio, weight, Polycystic Ovary Syndrome Questionnaire, Measure Yourself Medical Outcome Profile, Dermatology Life Quality Index, Morisky Medication Adherence Scale, modified Ferriman-Gallwey scale, liver and kidney function, practitioner-blinding questionnaire and participant feedback forms. Process data will also inform feasibility such as recruitment rate, completion rate and reasons for dropout. Statistical analysis will be piloted in this study. We will present descriptive statistics for primary and secondary variables and use analysis of variance and Chi-squared tests where appropriate. Results and Conclusion This study received ethical approval in December 2012. 40 participants were recruited between January 2013 and August 2013 and the study is expected to complete in March 2014.
    European Journal of Integrative Medicine 06/2014; 6(3). DOI:10.1016/j.eujim.2014.03.001 · 0.65 Impact Factor
Show more

Preview

Download
16 Downloads
Available from